Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors. (February 2017) - Forster, M.; Sessa, C.; Von Moos, R.; Brown, N.; Metaxas, Y.; Griguolo, G.; Lardelli, P.; Iglesias, J.; Fernandez-Teruel, C.; Jandali, U.; Soto-Matos, S.M.; Stathis, A.